Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 5.17%
As of Tuesday, July 21, C4 Therapeutics, Inc.’s CCCC share price has surged by 5.17%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Down 5.28%
As of Monday, July 20, C4 Therapeutics, Inc.’s CCCC share price has dipped by 5.28%, which has investors questioning if this is right time to buy.Michael Rose
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Down 5.66%
As of Thursday, July 16, C4 Therapeutics, Inc.’s CCCC share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Jenna Brashear
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Down 6.06%
As of Friday, July 10, C4 Therapeutics, Inc.’s CCCC share price has dipped by 6.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Down 11.49%
As of Wednesday, July 08, C4 Therapeutics, Inc.’s CCCC share price has dipped by 11.49%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $384.8 | $252.6 | 34% |
|
| Shares Out (Mil) | 126.1 | 52.3 | 67% |
|
| Institutional Ownership | 98.5% | 92.1% | 80% |
|
| Float (Mil) | 83.7 | 40.2 | 58% |
|
| Beta | 2.93 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 2,685 | 455 | 86% |
|
| Price Change (52-week) |
61.1% | 52.9% | 84% |
|
| Growth | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 1.6% | 13.6% | 22% |
|
| Net Income (5yr) | (9.6%) | (9.9%) | 29% |
|
| EPS (5yr) | 26.3% | 16.0% | 77 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (50.9%) | (15.6%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 4 | |
| Current EPS | ($0.230) | ($0.956) | ($1.040) | |
| Month Ago EPS | ($0.230) | ($0.956) | ($1.040) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.295) | ($1.113) | ($1.260) | |
| Year/Year Chg | 15.6% | (24.5%) | 3.4% | |
| Financials | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $38 | 17% |
|
| Net Income (TTM) (Mil) | ($104) | ($43) | 10% |
|
| EPS (TTM) | ($1.073) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($95) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $10 | $5 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $52 | $5 | 39% |
|
| Enterprise Value (Q1) (Mil) | $218 | $180 | 27% |
|
| Valuation | CCCC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.55 | 2.56 | 41% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 78.3% | 63.8% | 88% |
|
| Net Margin | (297.8%) | (67.3%) | 3% |
|
| ROA | (32.0%) | (49.8%) | 16% |
|
| ROE | (48.3%) | (55.5%) | 16% |
|
| Liabilities to Assets | 28.8% | 30.3% | 20% |
|
| F-Score | 2 | 3 | 7% |
|
C4 Therapeutics, Inc. did not pass any screens on 7/31/2026.
